Potency and safety considerations for iPSC-derived cell products
25 Sep 2024
Monterey
Cell Therapy Development
- What are the advantages and challenges for allogeneic vs autologous iPSC-derived product?
- How should we determine appropriate genomic integrity assessment from end to end process?
- What new analytical methods could improve our ability to characterize identified CQA?
- Is this critical to have fully matured cells (terminally differentiated cells) as a product?
Industry Expert
